Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer

Compared with crizotinib, lorlatinib may be a cost-effective first-line treatment choice for advanced ALK-positive NSCLC in China.

Authors

Institutions

Publication Details

Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Published
2024-11-07
DOI
https://doi.org/10.1080/14737167.2024.2421389
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer

Hao Guo, Yuxiang Shang
Expert Review of Pharmacoeconomics & Outcomes Research
Lung Cancer Treatments and Mutations
article

Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer

Hao Guo, Yuxiang Shang
article en

Abstract

Compared with crizotinib, lorlatinib may be a cost-effective first-line treatment choice for advanced ALK-positive NSCLC in China.

Expert Review of Pharmacoeconomics & Outcomes ResearchVol. 25(3)
Inner Mongolia People's Hospital (CN), Baotou Medical College (CN)
Openalex Percentile: Top 62%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.